BioSelective Capital Investments completed the acquisition of California drug product development and manufacturing operations of BioDuro.

BioSelective Capital Investments, a risk-capital investment company, completed the acquisition of California drug product development and manufacturing operations of Advent-backed BioDuro, a provider of fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics. Financial terms were not disclosed. “This acquisition represents a meaningful expansion of our capabilities and reinforces our long-standing commitment to U.S.-based development, manufacturing, and supply of critical drug products for both domestic and global partners. We sincerely appreciate the collaborative engagement with BioDuro and its investors throughout this transaction and look forward to continuing the relationship as a trusted U.S. manufacturing partner for oral dosage forms,” Cyrus K. Mirsaidi, BioSelective Capital Investments Chairman.